Everstar Asset Management LLC Purchases 83,777 Shares of Aquestive Therapeutics, Inc. $AQST

Everstar Asset Management LLC raised its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 38.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 300,000 shares of the company’s stock after purchasing an additional 83,777 shares during the quarter. Everstar Asset Management LLC owned 0.30% of Aquestive Therapeutics worth $870,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. AQR Capital Management LLC grew its stake in shares of Aquestive Therapeutics by 12.2% in the first quarter. AQR Capital Management LLC now owns 129,019 shares of the company’s stock worth $374,000 after purchasing an additional 14,025 shares during the last quarter. DAFNA Capital Management LLC grew its stake in shares of Aquestive Therapeutics by 11.8% in the first quarter. DAFNA Capital Management LLC now owns 142,000 shares of the company’s stock worth $412,000 after purchasing an additional 15,000 shares during the last quarter. Stonepine Capital Management LLC grew its stake in shares of Aquestive Therapeutics by 25.0% in the first quarter. Stonepine Capital Management LLC now owns 200,000 shares of the company’s stock worth $580,000 after purchasing an additional 40,000 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Aquestive Therapeutics during the first quarter worth about $115,000. Finally, Pale Fire Capital SE raised its position in shares of Aquestive Therapeutics by 154.1% during the first quarter. Pale Fire Capital SE now owns 1,335,684 shares of the company’s stock worth $3,873,000 after acquiring an additional 809,928 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $5.42 on Monday. The business has a 50 day simple moving average of $3.98 and a 200 day simple moving average of $3.25. Aquestive Therapeutics, Inc. has a one year low of $2.12 and a one year high of $5.80. The stock has a market capitalization of $540.48 million, a P/E ratio of -7.74 and a beta of 1.82.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities analysts expect that Aquestive Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Oppenheimer assumed coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an “outperform” rating and a $7.00 price objective for the company. Zacks Research upgraded Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 13th. Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of “Buy” and an average target price of $10.14.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.